Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 billion, with upfront consideration of $1.25 billion representing a 107% premium to Amryt ADSs’ closing price of $7.00 on 6th January.
The transaction also includes Contingent Value Rights (CVRs) of up to an additional $2.50 per ADS, representing an approximate additional $225 million of potential consideration, based on certain milestones being achieved with Amryt’s Filsuvez, that will see the Italian company expand its rare disease medicine portfolio. Filsuvez is used to treat adults and children aged 6 months or older with epidermolysis bullosa (EB), an inherited skin disease that makes the skin very fragile and causes severe blistering and scarring.
